This review presents the current state of knowledge regarding multifunctional role of human skin antimicrobial peptides (AMPs), including (a) protection from microbial infection, (b) improvement of skin barrier homoeostasis, (c) modulation of inflammation responses, and (d) promotion of wound healing. In addition, association of AMPs with skin diseases as well as challenges and future prospects for AMP therapeutics has also been discussed.
| INTRODUC TI ON
Antimicrobial peptides (AMPs) are generally small in size amino acids), positively charged amphiphilic molecules with α-helix or β-sheet linear motifs and linear or cyclic configurations. 1 Several types of cationic AMPs including human β-defensins (hBD) 1-3, cathelicidin LL-37, ribonuclease RNase-7, and psoriasin (S100A7) as well as anionic AMP dermcidin were identified in the human skin. 2 They are produced by different resident cells of the skin such as keratinocytes (eg, LL-37, hBD 1-3), 3, 4 eccrine sweat gland and sweat ductal epithelial cells (eg, LL-37, dermcidin), 5, 6 sebocytes (eg, hBD-2 and hBD-3, histone H4), [7] [8] [9] neutrophils (eg, LL-37, hBD-2 and hBD-3), 10 and mast cells (eg, LL-37). 11 Some AMPs are permanently secreted onto the skin surface, and others are weakly expressed in the healthy skin but up-regulated through the various stimuli including microorganisms, 8, 12 proinflammatory cytokines, 13 vitamin D, 14 and UVB irradiation. 15 Moreover, epidermal differentiation, 16 wound healing, 17 infection, and tissue injury 17 AMP therapeutics has also been discussed.
| AMPS AC TIVIT Y IN THE S K IN

| Antimicrobial activity of AMPs
The skin is constantly exposed to commensal microflora and patho- 36 Moreover, unique peptides phenol-soluble modulins (PSM γ and PSM δ) produced by S. epidermidis can selectively inhibit the skin pathogens and help to maintain the normal skin microbiome. 37 This multi-directional mechanism of action of AMPs indicates that these peptides not only have low propensity to elicit microbial adaptation but also are able to neutralize exotoxins and endotoxins produced by microbes.
38,39
| AMPs and skin barrier
In recent years, it has been found that AMPs and permeability barriers of the skin are closely linked. 29, 40 The tape stripping, acetone treatment, and essential fatty acid-deficient diet induce skin barrier disruption that leads to a moderate induction of mice mBD-1 and mBD-14 and a pronounced induction of mBD-3 mRNA. 41 In turn, artificial barrier repaired by occlusion significantly reduces the increased expression of mBD-14 after mechanical injury and of all mBDs in diet mice. Also, Aberg et al 42 observed that acute and chronic disruption of the physical skin barrier leads to inductions of CRAMP (the murine ortholog of LL-37) and mBD-3 (the murine ortholog of hBD-2). Moreover, the results of some studies indicate that the expression of AMPs in keratinocytes coincides with the presence and expression of a number of epidermal structural components (eg, involucrin, loricrin, keratin-1 and keratin-10, transglutaminase-1 and transglutaminase-3) that are part of the skin permeability barrier. 40 It was found that hBD-3 plays an important role in the skin barrier homoeostasis. 43 The hBD-3 increases the expression of tight junction (TJ) proteins-claudins, changes localization at the cell-cell borders as well reduces the paracellular permeability of keratinocyte layers. Moreover, hBD-3 enhances the activation of Rac1, atypical protein kinase C, glycogen synthase kinase-3, and phosphatidylinositol 3 kinase, which are required for the hBD-3-mediated regulation of the TJ barrier function. 43 Also, psoriasin regulates differentiation and strengthens the skin TJ barrier functioning through increased expression of TJ proteins (eg, claudins and occludin). 44 Furthermore, β-catenin and E-cadherin accumulation at cell-cell contact increased by psoriasin leads to reduced paracellular permeability of keratinocyte layers.
| AMPs and skin immune defense
Recent studies have revealed that cutaneous microbiota works together with the skin innate immune system and act as a barrier against overgrowth of pathogenic microbes. 45, 46 It was noted that commensal and pathogenic microorganisms evolved specific mechanisms to modulate innate immunity of the skin. 47 The Moreover, AMPs also initiate a potent host response to skin infection resulting in cytokine/chemokine production, inflammation, and a cellular response. 48, 49 After exposure to microbe-derived molecules, both monocytes and lymphocytes stimulated the epidermal expression of hBDs. 50 The hBD-2, hBD-3, and hBD-4 but and chemokines (MIP3α) through both G protein and p38/MAPK pathways. 54 
| Wound healing activity of AMPs
Human AMPs promote wound healing in the skin by bidirectional action, including (a) prevention of increased pathogen proliferation and biofilms formation in the injured skin 17 and (b) modulation of cytokine production, cell proliferation, and angiogenesis. 55, 56 Epidermal injury induces distinct human AMPs such as LL-37, hBD-2 and hBD-3, psoriasin, S100A8 (calgranulin A), S100A9 (calgranulin B), and S100A15. 57 The increased concentrations of LL-37 after skin injury are due to both synthesis within epidermal keratinocytes and deposition from granulocytes that migrate to the site of injury. 58 It was observed that LL-37 is closely linked to re-epithelization of skin wounds during the wound healing process via EGFR activation 59, 60 that promotes angiogenesis through activation of FPRL1 (formyl peptide receptor-like 1) and neovascularization of endothelial cells. 61 Moreover, LL-37-deficient mice have decreased vascularization during the process of wound healing 61 and increased susceptibility to bacterial colonization and infection. 21, 62 Furthermore, inhibition of LL-37 in wounded organ-cultured human skin resulted in impediment of re-epithelialization. 16 Also, hBD-2, hBD-3, and hBD-4 stimulate human epidermal keratinocyte migration, proliferation and proinflammatory chemokines and cytokines production via phosphorylation of EGFR and STAT proteins. 51, 63 Moreover, hBD-3 has been shown to exhibit in vitro and in vivo anti-inflammatory activities by inhibiting TLR signaling pathways in immune cells that result in transcriptional repression of proinflammatory genes and may contribute to resolution of inflammation. 64, 65 Also, increased expressions of psoriasin, S100A8, S100A9, and S100A15 were found in the injured skin. 57 The S100A7 stimulated keratinocytes differentiation after skin injury via the activation of TLR3 followed by the activation of p38/MAPK. 66 The increased expression of S100A8/A9 was found in differentiating suprabasal wound keratinocytes especially in the first 12-24 hours after injury. 67, 68 In in vivo studies, S100A15
was highly elevated in wounds 4 days after skin injury, whereas such increase was absent in ex vivo observations. This fact suggests that infiltration of inflammatory cells highly affected S100A15 expression, either by expressing this AMP itself or by releasing factors that trigger its induction in keratinocytes. 69 In contrast to increased AMPs expression in the injured skin, a reduced AMPs expression in human burn wounds was revealed. 70 The expression of hBD-2 is reduced or absent in acute burn wounds and blister fluid compared to non-burn wounds. 70, 71 Studies carried out on mice and humans have demonstrated that burn-induced myeloid cells are capable to suppress keratinocyte AMPs production. 72, 73 Similar to the burn margin, distal unburned skin from burned mice displayed greater cutaneous protease activity and altered AMP production, which paralleled a diminished ability to inhibit the growth of several skin microbes. 74 The increase in hBD-1, hBD-2, and RNAse 7, and the parallel decrease in LL-37 observed in burn margin may be caused by differences in the skin microbiome after burn injury. 75 The differences in AMPs expression in the injured and burned skin may result from quantitative changes in commensal microorganisms, but this hypothesis requires confirmation by further research.
| AMPS AND S KIN D IS E A S E S
The change in AMP expression in the skin may constitute an important factor in the pathogenesis of many skin diseases including acne vulgaris, atopic dermatitis (AD), and psoriasis. 76, 77 The expressions of hBDs and LL-37 are up-regulated in acne vulgaris and psoriasis, 4, 78, 79 on the contrary, their expressions are downregulated in AD. [80] [81] [82] There is an increasing evidence that AMPs may have an impact on acne pathogenesis. 83 The proliferation of bacteria Propionibacterium acnes, which produces lipase, hyaluronidase, and proteases and activates immune cells thereby triggering inflammation, is one of many factors included in the pathogenesis of acne. 84 P. acnes infection promotes increased expressions of hBD-1 and hBD-2 in the lesional skin 85, 86 and both hBD-2 and LL-37 in keratinocytes and sebocytes. 9, 87 Furthermore, the development and application of modified AMPs might be promising. On the one hand, AMPs are active against P. acnes, and on the other, they are able to inhibit P. acnes induced inflammation. 79 Atopic dermatitis is a chronic inflammatory skin disease associated with cutaneous hyperreactivity to environmental triggers and unique patient predisposition to S. aureus colonization or infection. 88, 89 Presence of S. aureus at AD skin lesion is associated with decreased expression of AMPs including LL-37, hBD-2 and hBD-3, RNase 7, psoriasin, and dermcidin. [90] [91] [92] [93] This fact supports the hypothesis that deficiency of AMPs contributes to the increased susceptibility of AD skin to S. aureus infection. 82, 94 In turn, up-regulation of psoriasin on the surface of AD skin explains the lack of E. coli skin infection in AD patients and appears only after skin barrier disruption. 27, 95 Moreover, the lack of major AMPs inducers in AD skin, such as IL-1, IL-17, and IL-22, and suppression of AMPs induction by elevated levels of T-helper 2 cytokines observed in vitro for IL-4, IL-10, and IL-13, may explain the lower AMP levels in AD patients. 96 Psoriasis is a chronic inflammatory skin disease characterized histologically by hyperproliferation and aberrant differentiation of epidermal keratinocytes. 97 The LL-37, hBD-2, and hBD-3 as well as psoriasin were found to be dominating AMPs in lesional psoriatic skin that contribute to modulation of host defense, particularly during inflammation/infection. 78, 80 The psoriasin is highly up-regulated in psoriatic skin and multifunctional modulator of neutrophil activation. 98, 99 It was found that psoriasin activates neutrophils to produce a range of cytokines and chemokines including IL-6, IL-8/ CXCL8, TNF-α, MIP-1α/CCL3, MIP-1β/CCL4, and MIP-3α/CCL20. 
| THER APEUTI C AL AC TIVIT Y OF AMPS
Antimicrobial peptides may be attractive candidates for novel therapeutic approaches as a pathogen-specific antibiotics for skin infections, immune modulators, and active agent for wound healing in humans. 100, 101 Due to the increasing development of resistance to classical antibiotics, AMPs and their synthetic derivatives are very interesting for practical applications as a new generation of antimicrobial drugs for skin infections. 102, 103 AMPs possess qualities that make them excellent candidates for antibacterial therapeutics, including their broad spectrum of antimicrobial activity, rapid bactericidal activity, and low propensity for resistance development. 104 The examples of AMPs with topical applications against microbial infections are as follows: gramicidin incorporated into a di- Antimicrobial peptides are crucial components of the innate immune system and may be successfully used as immune modulators. 100, 112 In this case, the up-regulation of certain innate immune mechanisms while suppressing proinflammatory cytokine responses offers an exciting and interesting approach to anti-infective therapy-a therapy that does not incite resistance (peptides act through a diverse innate immune system rather than directly on bacteria). 113 Unfortunately, there are no literature data or preclinical/clinical studies that would present AMPs as potential therapeutics for inflammatory skin diseases.
However, there are several studies confirming therapeutic potential of AMPs as modulators of wound healing in humans. 17 Due to antimicrobial activity, AMPs are attractive candidates, possibly superior to conventional antibiotics, for the local treatment of infected skin wounds. 17 Topical treatment of diabetic patients with a mildly infected foot ulcer with pexiganan cream (2%) showed comparable clinical effectiveness to oral antibiotic therapy with ofloxacin. 114 Nisin containing nanofiber wound dressings reduces S. aureus bioluminescence in vivo and viable cell numbers in a murine excisional skin infection model. 115 The bactenecin-derived peptide IDR-1018 demonstrates significantly accelerated process of wound healing in methicillin-sensitive S. aureus infected porcine but not in diabetic murine wounds. 116 Also, treatment of diabetic and acute skin flap wounds of rats with SR-0379 significantly accelerates wound healing through enhanced angiogenesis, granulation tissue formation and proliferation of endothelial cells and fibroblasts. 117 In some studies, the use of LL-37 in regard to wound healing in hard-to-heal venous leg ulcers 118 through increased vascularization and re-epithelialization of skin after injury was described. 119 
| CON CLUS IONS
Antimicrobial peptides due to their antimicrobial activity not only kill skin pathogens but also initiate a potent host response to skin infection. This response results in cytokine release, inflammation and in consequence leads to a cellular response. These features of AMPs are actively involved in maintaining of the skin barrier homeostasis. Furthermore, imbalanced skin microflora affect AMP expression in the skin, which is critical in the pathogenesis of many skin diseases, including acne vulgaris, AD, or psoriasis.
The understanding of the pathophysiology of skin diseases associated with AMPs will enable to exploit AMPs for therapeutic purposes and expand conventional treatments for skin conditions. AMPs may be attractive candidates for novel therapeutic approaches as a pathogen-specific antibiotics for skin infections, immune modulators, and active agents for wound healing in humans. Unfortunately, the great potential of AMPs usefulness as a new class of therapeutics still remains to be proven.
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